mage-1 antibody  (NSJ Bioreagents)

Journal: Cancers

Article Title: Innovative Cancer Immunotherapy with MAGE-A3 mRNA Cancer Vaccines.

doi: 10.3390/cancers16193428

Figure Lengend Snippet: Figure 1. Melanoma-associated antigen A3 (MAGE-A3) mRNA synthesis. (A) Utilizing the IVT method for synthesizing GFP mRNA, the entire MAGE-A3 coding sequence was incorporated into the plasmid via subcloning. (B) Following sequencing and gene alignment, successful insertion of MAGE-A3 was confirmed.

Article Snippet: After blocking, the membranes were incubated with a 1:1000 dilution of anti-MAGE-A3 antibodies (Proteintech, Rosemont, IL, USA) and then with a 1:3000 dilution of anti-GAPDH mouse antibodies (Millipore, Darmstadt, Germany) in TBST containing 3% skim milk at 4 ◦C overnight.

Techniques: Sequencing, Plasmid Preparation, Subcloning

Journal: Cancers

Article Title: Innovative Cancer Immunotherapy with MAGE-A3 mRNA Cancer Vaccines.

doi: 10.3390/cancers16193428

Figure Lengend Snippet: Figure 2. Relative expression of MAGE-A3 after in vitro mRNA transfection. (A) RNA and protein expression following transfection with various prepared LNPs and MAGE-A3 mRNA measured for 72 h. (B) Stability of varied LNPs/MAGE-A3 mRNA complexes refrigerated for 16 weeks was evaluated in terms of RNA transcription and protein production.

Article Snippet: After blocking, the membranes were incubated with a 1:1000 dilution of anti-MAGE-A3 antibodies (Proteintech, Rosemont, IL, USA) and then with a 1:3000 dilution of anti-GAPDH mouse antibodies (Millipore, Darmstadt, Germany) in TBST containing 3% skim milk at 4 ◦C overnight.

Techniques: Expressing, In Vitro, Transfection

Journal: Cancers

Article Title: Innovative Cancer Immunotherapy with MAGE-A3 mRNA Cancer Vaccines.

doi: 10.3390/cancers16193428

Figure Lengend Snippet: Figure 3. Preventive effects of MAGE-A3 mRNA-containing LNPs on tumor growth. (A) Experimen- tal design of immunization and challenge of CT26 tumor cells in mice. The changes in (B) tumor size and (C) body weight were monitored for 28 d. * p < 0.05.

Article Snippet: After blocking, the membranes were incubated with a 1:1000 dilution of anti-MAGE-A3 antibodies (Proteintech, Rosemont, IL, USA) and then with a 1:3000 dilution of anti-GAPDH mouse antibodies (Millipore, Darmstadt, Germany) in TBST containing 3% skim milk at 4 ◦C overnight.

Techniques:

Journal: Cancers

Article Title: Innovative Cancer Immunotherapy with MAGE-A3 mRNA Cancer Vaccines.

doi: 10.3390/cancers16193428

Figure Lengend Snippet: Figure 4. Histopathological analysis of major internal organs and tumors in mice treated with the mRNA anticancer vaccine. (A) On the 28th day post-inoculation, major organs were harvested from tumor-bearing mice and processed for histopathological examination. Magnification: ×100 (scale bar = 100 µm). (B) Tumor tissues extracted from vaccinated mice were analyzed immunohistochemically using an antibody specific to MAGE-A3. Magnification: ×200 (scale bar = 100 µm).

Article Snippet: After blocking, the membranes were incubated with a 1:1000 dilution of anti-MAGE-A3 antibodies (Proteintech, Rosemont, IL, USA) and then with a 1:3000 dilution of anti-GAPDH mouse antibodies (Millipore, Darmstadt, Germany) in TBST containing 3% skim milk at 4 ◦C overnight.

Techniques:

Journal: Cancers

Article Title: Innovative Cancer Immunotherapy with MAGE-A3 mRNA Cancer Vaccines.

doi: 10.3390/cancers16193428

Figure Lengend Snippet: Figure 5. Survival of mice immunized with MAGE-A3 mRNA and then challenged with tumor cells. (A) Schematic image of immunized mice were intravenously injected with CT26 cells to artificially induce a tumor metastasis model. (B) Survival rate of the mice vaccinated with MAGE-A3 mRNA in various LNPs were intravenously injected with CT26 cells to induce tumor metastasis artificially. (C) Entire livers and lungs with tumors were observed before (upper) and after (bottom) fixation in Bouin’s solution with picric acid. Tumors were identified and marked with white arrows. Tumors typically presented as dark red or white nodules and appeared as bright-yellow nodules upon fixation with Bouin’s solution. * p < 0.05, ** p < 0.01.

Article Snippet: After blocking, the membranes were incubated with a 1:1000 dilution of anti-MAGE-A3 antibodies (Proteintech, Rosemont, IL, USA) and then with a 1:3000 dilution of anti-GAPDH mouse antibodies (Millipore, Darmstadt, Germany) in TBST containing 3% skim milk at 4 ◦C overnight.

Techniques: Injection

Journal: Cancers

Article Title: Innovative Cancer Immunotherapy with MAGE-A3 mRNA Cancer Vaccines.

doi: 10.3390/cancers16193428

Figure Lengend Snippet: Figure 7. Histopathological examination of major internal organs and tumors of mice injected with MAGE-A3 mRNA vaccine. (A) Twenty-two days after the first treatment with MAGE-A3 mRNA vaccines, major organs were collected from the tumor-bearing mice. The organs were paraffin- embedded, sectioned, and subjected to H&E staining for histopathological analysis. Magnification: ×100 (scale bar = 100 µm). (B) Tumor tissues were immunohistochemically stained using an anti- MAGE-A3 antibody and examined under a light microscope for detailed analysis. Magnification: ×200 (scale bar = 100 µm).

Article Snippet: After blocking, the membranes were incubated with a 1:1000 dilution of anti-MAGE-A3 antibodies (Proteintech, Rosemont, IL, USA) and then with a 1:3000 dilution of anti-GAPDH mouse antibodies (Millipore, Darmstadt, Germany) in TBST containing 3% skim milk at 4 ◦C overnight.

Techniques: Injection, Vaccines, Staining, Light Microscopy